XPO1: From basic research to clinical treatment (Review)
Changyan Yang, Jing Zhu, Xiang Zheng, Xiaochen Hou, Jiumei Zhao, Youfu Pan, Yu Tang · 2026
Read XPO1: From basic research to clinical treatment (Review) by Changyan Yang, Jing Zhu, Xiang Zheng, Xiaochen Hou, Jiumei Zhao, Youfu Pan, Yu Tang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13443291.txt.
Description
Changyan Yang and colleagues review XPO1, a cell export gate, as a cancer drug target in a 2026 paper. The gate ships tumor guards such as p53 and Rb out of the cell core, where they lose their voice. Many cancers overbuild or overfire the gate, which frees growth and blunts cell death.
Blocker drugs, called SINE compounds, jam the gate and trap guards back in the core. The lead drug, selinexor, has reached clinic use in blood cancers and faces tests in solid tumors. Solo use shows caps, from harm to weak reach. The review weighs paired plans that may lift gains, plus trial paths ahead. The authors frame gate jamming as a young but real arm of cancer care.
Catalog record
| CREATOR | Changyan Yang, Jing Zhu, Xiang Zheng, Xiaochen Hou, Jiumei Zhao, Youfu Pan, Yu Tang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |